The effect of different Esorubicin concentrations (10-7 M to 10-10 M) has been tested on the in vitro growth of human normal hemopoietic progenitor cells and of three leukemic cell lines (K562, U 937, HL60). The highest drug concentration completely abolished both normal and leukemic proliferation. Lower doses of Esorubicin failed to induce any morphological or phenotypic differentiation of leukemic cell lines. A 24 h pretreatment of the cells with 10-9 M Esorubicin enhanced the in vitro proliferation of normal early myeloid progenitor cells, whereas it did not affect leukemic, myelomonocytic cell proliferation.
|Number of pages||4|
|Publication status||Published - 1988|
ASJC Scopus subject areas
- Cancer Research